Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could inhaled gases help COVID-19 patients breathe easier and survive?

NCT ID NCT04415060

Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving inhaled anesthetics (isoflurane or sevoflurane) to sedate COVID-19 patients on ventilators can improve survival and reduce time on the breathing machine compared to standard IV sedatives. About 800 adults in the ICU with lung failure will be randomly assigned to receive either inhaled or IV sedation. The goal is to see if the inhaled approach leads to better outcomes and eases pressure on limited drug supplies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Isoflurane or Sevoflurane (inhaled anesthetics)
What this could lead to
If it works, this could provide a widely available alternative to IV sedatives, potentially improving survival and freeing up ventilators faster.
What could go wrong
This is an early-stage phase 3 trial with 800 participants, and results may not show a clear benefit. Inhaled anesthetics can have side effects like low blood pressure or breathing issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2020

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥ 18 years of age 2. Mechanically ventilated and expected to remain mechanically ventilated at the end of the next day 3. Receiving IV sedation by infusion or bolus for ≤72 hours to facilitate mechanical ventilation Transferred patients with escalating ventilation needs are eligible for recruitment within ≤72 hours of sedation commenced within the participating trial site that they were transferred to. Note: Intravenous sedation required to support mechanical ventilation includes use of one or more of the following agents: benzodiazepines, propofol, ketamine, barbiturates, alpha-2 agonist, opioids. Patients receiving intravenous opioids only i.e., fentanyl ≥ 50mcg/hour, hydromorphone ≥ 0.4mg/hour (or bolus q1h) for analgesia and sedation or agitation to assist mechanical ventilation are eligible for inclusion. 4. Mechanically ventilated patients +/- extracorporeal membrane oxygenation (extracorporeal life) support with: 1. Proven or suspected (under investigation) COVID-19, or 2. COVID-19 negative patients who have a PaO2FiO2 ratio ≤300 measured with arterial blood gas at least once during the 12 hours prior to enrollment. Note: If arterial blood gas measurement is unavailable, the PaO2 can be imputed from the pulse oximetry measurement Exclusion Criteria: 1. Contraindications to sedatives, such as propofol infusion syndrome or malignant hyperthermia; 2. Known allergy to any of the ingredients or components of the investigational products; sevoflurane or isoflurane; 3. Suspect or evidence of high intracranial pressure; 4. Severe brain injury that is likely to lead to sustained very low conscious levels or vegetative state 5. Severe neuromuscular disorder for example amyotrophic lateral sclerosis, Gullian Barre Syndrome that are the primary cause of needing ICU admission and mechanical ventilation 6. One-lung ventilation or pneumonectomy; 7. Ideal estimated tidal volume too low for delivery of inhaled agents. Target (6ml/kg) \< 200ml; 8. Use of inhaled prostacyclin which is contraindicated in the presence of a miniature vaporizer (i.e., Anesthesia Conserving Device). This agent has a high viscosity that leads to poor vaporization of the volatile agent. Note: Other inhaled pulmonary vasodilators such as nitric oxide can be safely administered in the presence of miniature vaporizers. Use of prostacyclin is permissible with an anesthesia machine and MADM; 9. Known pregnancy 10. Moribund patient not expected to survive \>12 hours

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 Hypoxic respiratory failure

Contacts and locations

Locations

  • Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, H2X 3E4, Canada

  • Grey Nuns Community Hospital

    Edmonton, Alberta, T6L 5X8, Canada

  • Hôpital Sacré-Coeur de Montréal

    Montreal, Quebec, H4J1C5, Canada

  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ)

    Québec, Quebec, G1V 4G5, Canada

  • London Health Sciences Centre - University Hospital

    London, Ontario, N6A 5A5, Canada

  • London Health Sciences Centre - Victoria Hospital

    London, Ontario, Canada

  • McGill University Health Centre - Royal Victoria Hospital

    Montreal, Quebec, H4A 3J1, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N3M5, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Universite de Sherbrooke

    Sherbrooke, Quebec, J1K 2R1, Canada

  • University Health Network - Toronto General Hospital

    Toronto, Ontario, M5G 2C4, Canada

  • University Health Network - Toronto Western Hopsital

    Toronto, Ontario, M5T 2S8, Canada

  • University of Alberta Hospital

    Edmonton, Alberta, T6G 2B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.